• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Elevai Labs Inc.

    9/26/24 6:28:15 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    SC 13G 1 altium-sc13g_092624.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

    Elevai Labs Inc.

    (Name of Issuer)

     

     
    Common Stock, par value $0.0001
    (Title of Class of Securities)
     

     

    28622K104

    (CUSIP Number)

     

     
    September 23, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 2 of 9

    CUSIP No.    28622K104  

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99%(1)(2)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

    (1) As more fully described in Item 4, the Pre-Funded Warrants are subject to a 9.99% blocker (the “PFW Blocker”). The Series A Warrants and Series B Warrants (collectively, with the Pre-Funded Warrants, the “Warrants”) are each subject to a 4.99% blocker (the “Series Blocker” and collectively, with the PFW Blocker, the “Warrant Blockers”). However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and does not give effect to the Warrant Blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such Warrant Blockers, is less than the number of securities reported in rows (6), (8) and (9).
       
    (2) Based on 49,376,039 shares of Common Stock outstanding as of September 22, 2024 as set forth in the Issuer’s Form 42B4(4), filed with the Securities and Exchange Commission (“SEC”) on September 24, 2024.

     

     

    Page 3 of 9

    CUSIP No. 28622K104    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99%(1)(2)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    (1)As more fully described in Item 4, the Pre-Funded Warrants are subject to a 9.99% blocker (the “PFW Blocker”). The Series A Warrants and Series B Warrants (collectively, with the Pre-Funded Warrants, the “Warrants”) are each subject to a 4.99% blocker (the “Series Blocker” and collectively, with the PFW Blocker, the “Warrant Blockers”). However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and does not give effect to the Warrant Blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such Warrant Blockers, is less than the number of securities reported in rows (6), (8) and (9).
      
    (3)Based on 49,376,039 shares of Common Stock outstanding as of September 22, 2024 as set forth in the Issuer’s Form 42B4(4), filed with the Securities and Exchange Commission (“SEC”) on September 24, 2024.

     

     

    Page 4 of 9

     

    CUSIP No. 28622K104    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,257,519 shares of Common Stock

    3,414,285 shares of Common Stock issuable up conversion of Pre-Funded Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series A Warrants(1)

    5,714,285 Shares of Common Stock issuable upon exercise of Series B Warrants(1)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99%(1)(2)

     
    12

    TYPE OF REPORTING PERSON

    OO

     


     

    (1)As more fully described in Item 4, the Pre-Funded Warrants are subject to a 9.99% blocker (the “PFW Blocker”). The Series A Warrants and Series B Warrants (collectively, with the Pre-Funded Warrants, the “Warrants”) are each subject to a 4.99% blocker (the “Series Blocker” and collectively, with the PFW Blocker, the “Warrant Blockers”). However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and does not give effect to the Warrant Blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such Warrant Blockers, is less than the number of securities reported in rows (6), (8) and (9).
      
    (4)Based on 49,376,039 shares of Common Stock outstanding as of September 22, 2024 as set forth in the Issuer’s Form 42B4(4), filed with the Securities and Exchange Commission (“SEC”) on September 24, 2024.

     

     

    Page 5 of 9


    CUSIP No.
    28622K104    

    Item 1(a).   Name of Issuer:                                                         Elevai Labs Inc. (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices: 120 Newport Center Drive, Ste. 250

    Newport Beach, CA

         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.0001 (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 28622K104
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

    Page 6 of 9

    CUSIP No. 28622K104    

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership.
       
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 49,376,039 shares of Common Stock outstanding as of September 22, 2024 as set forth in the Issuer’s Form 42B4(4), filed with the Securities and Exchange Commission (“SEC”) on September 24, 2024.

     

    Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased Common Stock, Pre-Funded Warrants, Series A Warrants and Series B Warrants. As described above the Reporting Persons are subject to Warrant Blockers and as a result cannot exercise the Series A and Series B Warrants to the extent the Reporting Persons would beneficially own, after any such conversion or exercise, more than 4.99% of the outstanding shares of Common Stock. Further, as described above the Reporting Persons cannot exercise the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such conversion or exercise, more than 9.99% of the outstanding shares of Common Stock.

     

     

    Page 7 of 9

    CUSIP No . 28622K104    

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      Dated: September 26, 2024

     

      By: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: CEO

     

    Altium Growth Fund, LP

      By: Altium Growth GP, LLC
      Its: General Partner

      Signature: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: Managing Member of Altium Growth GP, LLC

      Altium Growth GP, LLC

      By: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: Managing Member

     

     

    Page 8 of 9

    EXHIBIT INDEX

    EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     
    Get the next $ELAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    Leadership Updates

    Live Leadership Updates

    See more
    • PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

      NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

      2/27/25 8:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

      Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

      7/30/24 9:00:26 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

      NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

      6/14/24 9:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & CFO Bensler Graydon was granted 3,036,437 units of Series B Preferred Stock (SEC Form 4)

      4 - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:52:32 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: New insider Bensler Graydon claimed ownership of 983,120 shares (SEC Form 3)

      3/A - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:51:28 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Braeden Lichti was granted 3,336,437 units of Series B Preferred Stock (SEC Form 4)

      4 - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:47:45 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      11/14/24 5:53:26 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      10/2/24 4:01:03 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      10/1/24 4:01:02 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    SEC Filings

    See more
    • PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      5/16/25 2:58:06 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by PMGC Holdings Inc.

      10-Q - PMGC Holdings Inc. (0001840563) (Filer)

      5/14/25 4:04:34 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      5/13/25 4:50:52 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

      NEWPORT BEACH, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), today announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic. The analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva Biosciences' MitoNova™, provided valuable insights into EL-22's proposed mechanism of action and will help guide further exploration into its potential to address critical unmet needs in muscle-wasting co

      5/22/25 8:16:33 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q

      NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our") today announced that it has filed its Quarterly Report on Form 10-Q ("Quarterly Report") for the three months ended March 31, 2025, with the U.S. Securities and Exchange Commission ("SEC"). The Quarterly Report is available on the SEC's website at www.sec.gov under the company's filings, as well as on the Company's investor relations website. Management believes the Company is well-capitalized, with a strong balance sheet and a clearly defined business focus. Through its operating subsidiaries, the Company is advancing its strategic growth priorities and ac

      5/14/25 4:30:00 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

      NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital," "we," "our," or "us"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (NASDAQ:TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company's outstanding shares of common stock, based on Alaunos' Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission, indicating 1,639,521 shares of common stock outstanding as of May 5, 2025.

      5/14/25 8:00:00 AM ET
      $ELAB
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Financials

    Live finance-specific insights

    See more
    • Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

      Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR

      5/1/24 9:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care